Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP/BGP Company Profiles - Data

From Commons Based Research
Jump to navigation Jump to search

Celera

Amgen

Who

  • 16,900 employees (2008 Corporate report)
  • History of acquisition (http://www.amgen.com/about/acquisitions.html):
    • 1994 - Synergen, Inc.
    • 2000 - Kinetix Pharmaceuticals, Inc.
    • 2002 - Immunex Corporation
    • 2004 - Tularik, Inc.
    • 2006 - Abgenix, Inc.
    • 2006 - Avidia, Inc.
    • 2007 - Ilypsa, Inc.
    • 2007 - Alantos Pharmaceuticals Holdings, Inc.
  • Subsidiaries (http://www.fundinguniverse.com/company-histories/Amgen-Inc-Company-History.html):
    • Amgen Australia Pty Ltd.;
    • Amgen N.V.; Amgen Canada Inc.;
    • Amgen Greater China Ltd.;
    • Amgen GmbH (Germany);
    • Amgen S.A. (France);
    • Amgen S.p.A. (Italy);
    • Amgen K.K. (Japan);
    • Amgen B.V. (Netherlands);
    • Amgen-Biofarmaceutica (Portugal);
    • Amgen S.A. (Spain);
    • Amgen (Europe) AG (Switzerland);
    • Kirin-Amgen, Inc. (Switzerland);
    • Amgen Limited (U.K.);
    • Amgen Sales Corporation (West Indies).
  • Unlike many biotech companies, has been consistently profitable. Net profit in 2006 was US$2.9Billion (http://www.pharmaceutical-business-review.com/companyprofile.asp?guid=8632C7AC-1633-4198-8551-BB79570C668D)
  • Managed to turn itself from a drug research company into a pharmaceutical company while maintaining steady sales - extremely rare in the industry (http://www.fundinguniverse.com/company-histories/Amgen-Inc-Company-History.html)
    • Founded in 1980. By 1986 was starting to turn a profit, but did so not through drug development but through research partnerships with established pharma firms
    • 1987, develop erythropoietin (EPO), which stimulates red blood cell creation. Sold the marketing rights to Johnson&Johnson
    • Epogen proves to hugely popular - over $250m in sales in 1991 alone
    • Between 1992 and 1996, Amgen's R&D budget goes from $182 million to $663 million

What

  • ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline
    • drugs include: Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara and Nplate
  • As a side-result of this research, also publishes in academic journals (e.g. http://en.scientificcommons.org/40666678)

Where

  • Thousand Oaks, CA

News

Commons-Based, Peer-Production, and Open Access News

Genentech

Who

What

Where

  • South San Francisco

News

Commons-Based, Peer-Production, and Open Access News

Genzyme

Who

  • 2007, US$2.89B operating income, $3.81B revenue ("Genzyme," Wikipedia)

What

  • Cerezyme (treats Gaucher's disease) accounts for 30% of company's revenue
  • Renagel, for dialysis patients
  • Fabrazyme, for Fabry's disease

Where

  • Cambridge

News

Commons-Based, Peer-Production, and Open Access News

Gilead Sciences

Who

What

  • Products for HIV/AIDS, respiratory and heart conditions, and liver disease
  • Over a dozen drugs in the development pipeline, Phase I or later

Where

  • Foster City, California

News

  • 1990 reaches agreement with Glaxo to research and develop "antisense" -- genetic code blockers
  • Goes public in 1992
  • 1996 - first commercial product, Vistide, treats cytomegalovirus
  • 1999 - acquires NeXstar Pharmaceuticals
  • 2003 acquires Triangle Pharmaceuticals
  • 2006, FDA approves Atripla for HIV-victims
  • 2006 acquires Corus Pharma, Inc.
  • 2006 acquires Myogen, Inc.
  • 2006 acquires Raylo Chemicals, a pharma producer - is Gilead Sciences trying to become a pharma company?

Commons-Based, Peer-Production, and Open Access News

Biogen Idec

Who

What

  • Treatments for Multiple Sclerosis, Crohn's disease, and a treatment for non-Hodgkin's lymphoma which is co-marketed with Genentech
  • Most revenue derived from Avonex, it's MS treatment

Where

  • Kendall Scquare, Cambridge
  • from Wikipedia: commercial affiliates in "Germany, France, Spain/Portugal, UK/Ireland, the Benelux, Sweden, Denmark, Norway, Finland, and Austria"
  • Research centers in San Diego and Research Triangle Park, N.C.

News

  • 2003, Biogen and IDEC merge

Commons-Based, Peer-Production, and Open Access News

Cephalon

Who

What

Where

News

Commons-Based, Peer-Production, and Open Access News

MedImmune

Who

What

Where

News

Commons-Based, Peer-Production, and Open Access News

Celgene

Who

What

Where

News

Commons-Based, Peer-Production, and Open Access News

Abraxis BioScience

Who

What

Where

News

Commons-Based, Peer-Production, and Open Access News

ImClone Systems

Who

What

Where

News

Commons-Based, Peer-Production, and Open Access News

Navigation

IP Profile of Biggest for-profit companies in BGP

Biotechnology - Genomic and Proteomics

Main Page